Try GOLD - Free
SINGAPORE TAKES ON CANCER WITH INNOVATIVE STREAK
BioSpectrum Asia
|BioSpectrum Asia July 2021
Although 2020 was more focused on finding solutions to fight the COVID-19 pandemic, it also pushed the boundaries of cancer prevention, diagnosis and treatment. Researchers across Asia have continued to make meaningful strides against cancer in 2020. One such remarkable example is that of Singapore. The scientific community across the country is setting new examples of innovation by focusing majorly on two aspects- chemotherapy and immunotherapy, to fight this deadly disease. While the socioeconomic burden inflicted by cancer is inevitable, Singapore’s innovative streak for developing effective treatment of cancer is set to mitigate this socioeconomic impact, and help patients maintain their quality of life, and remain productive.
Worldwide, an estimated 19.3 million new cancer cases and almost 10 million cancer deaths occurred in 2020, as per the GLOBOCAN 2020 report. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7 per cent), followed by lung (11.4 per cent), colorectal (10 per cent), prostate (7.3 per cent), and stomach (5.6 per cent) cancers. The global cancer burden is expected to be 28.4 million cases in 2040, a 47 per cent rise from 2020.
For both sexes combined, one-half of all cases and 58.3 per cent of cancer deaths are estimated to occur in Asia in 2020, where 59.5 per cent of the global population resides. In contrast to other regions, the share of cancer deaths in Asia (58.3 per cent) and Africa (7.2 per cent) are higher than the share of incidence (49.3 per cent and 5.7 per cent, respectively) because of the different distribution of cancer types and higher case fatality rates in these regions.
Although 2020 was more focused on finding solutions to fight the COVID-19 pandemic, it pushed the boundaries of cancer prevention, diagnosis and treatment. Researchers across Asia have continued to make meaningful strides against cancer in 2020. One such remarkable example is that of Singapore.
Due to the innovations arising within the region as well as the world-renowned healthcare system that the country boasts, Singapore attracts a myriad of medical professionals, academic researchers and healthcare-focused companies.
This story is from the BioSpectrum Asia July 2021 edition of BioSpectrum Asia.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM BioSpectrum Asia
BioSpectrum Asia
Alphamab Oncology appoints Fei Wang as Chief Financial Officer
Hong Kong-based Alphamab Oncology has announced the appointment of Fei Wang as the Chief Financial Officer (CFO).
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
CarbGeM inks MoU with DSS Imagetech to expand AI business in Indian market
DSS Imagetech, a leading player in medical and research imaging equipment, has announced the signing of a Memorandum of Understanding (MoU) with Japan-based CarbGeM Inc., a developer of artificial intelligence (AI)-powered life science solutions to expand its AI business in the Indian market.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
PHCbi introduces LiCellGrow Cell Expansion System
PHC Corporation's Biomedical Division, a global provider of laboratory sample storage and cell cultivation solutions and subsidiary of Japan's PHC Holdings Corporation, has announced the launch of its new cell expansion system LiCellGrow for research use in Japan and other select countries worldwide.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
CitiusTech appoints Dhaval Shah as Chief Business Officer - MedTech & Life Sciences
CitiusTech, a leading provider of healthcare technology services driving digital and AI excellence in India, has appointed Dhaval Shah to Chief Business Officer - MedTech & Life Sciences.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Thermo Fisher expands immunodiagnostics operations with new distribution centre in Uppsala
Thermo Fisher Scientific Inc. has announced the opening of a new 8,000-square-meter distribution & labeling centre supporting its immunodiagnostics business in Uppsala.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Harbour BioMed appoints Dr Jenny Xie as Head of Global External Innovation
Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced the appointment of Dr Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Argo Biopharma ropes in Dr Gena Wang as CFO and CSO
China-based Argo Biopharmaceutical Co., a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, has announced the appointment of Dr Gena Wang as Chief Financial Officer (CFO) and Chief Strategy Officer (CSO), effective March 1, 2026.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
IISc launches "Moonshot" project on brain co-processors supported by Pratiksha Trust
The Indian Institute of Science (IISc), Bengaluru has launched an ambitious \"moonshot\" project to develop brain co-processors that combine neuromorphic hardware and artificial intelligence (AI) algorithms to enhance or restore brain function.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Korea designs model for accurate and scalable drug-drug interaction prediction
A research team from the School of International Engineering and Science at Jeonbuk National University (JBNU), South Korea, has developed DDINet, a lightweight and scalable model, specifically designed to predict interactions for new, unseen drugs.
1 min
BioSpectrum Asia April 2027
BioSpectrum Asia
Australia-Singapore study advocates role of intranasal vaccine booster against sarbecoviruses
Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Monash University in Australia, have demonstrated that an intranasal vaccine booster may confer significantly stronger and broader immune responses, and provide robust neutralising antibody and resident T cell responses in the lung and nasal tissues, outperforming conventional mRNA booster vaccination.
1 min
BioSpectrum Asia April 2027
Translate
Change font size
